Key Highlights

  • 14.13% is the indicated pre-market gain for DNA X, Inc. (NASDAQ:SONM) on November 17, 2026, lifting the price to USD 2.40 from a calculated prior close of USD 2.10, a USD 0.30 move.
  • 2 preferred stock financing steps followed: a USD 3.1 million convertible note converted at USD 6.00 per share in July, and preferred sales at USD 6.00 per share raised USD 5.0 million in July and August 2026.
  • 1,488,268 common shares were outstanding at June 30, 2026 versus 1,265,067 at December 31, 2025, following a 1-for-18 Reverse Stock Split that took effect October 28, 2025.
  • 1 quarterly loss narrowed sharply: the second-quarter 2026 net loss was USD 1.25 million, or USD 0.92 per share, versus USD 7.5 million and USD 14.15 per share a year earlier, with cash of about USD 0.9 million.

What Moved DNA X, Inc. (NASDAQ:SONM) in Pre-Market Trading on November 17, 2026 (+USD 0.30, +14.13%)

The indicated pre-market price for DNA X, Inc. (NASDAQ:SONM) is USD 2.40 on November 17, 2026, a pre-market move of +14.13%. The calculated prior close is USD 2.10 (USD 2.40 divided by 1.1413), and the calculated USD move is +USD 0.30. Published coverage cited a 52-week range of USD 2.52 to USD 16.97, so the indicated price is below the low of that range. A corroborated market Capitalization and pre-market Volume were not found.

The Rationale: No Same-Day Catalyst Identified Amid the AI Platform Transition for DNA X, Inc. (NASDAQ:SONM)

No catalyst for the November 17, 2026 move was identified in published coverage. The company sold its legacy mobile device business, closed in January 2026, and is preparing to relaunch an AI-driven trading platform that automates trading strategies. The platform was closed to the public during the second quarter, so continuing-operations Revenue was zero, and management expected revenue to begin toward the end of the third quarter or early in the fourth quarter of 2026. Acting CEO Mike Mulica said the quarter marked an important milestone in securing capital and resources.

Valuation, Liquidity and Risks for DNA X, Inc. (NASDAQ:SONM)

Total Assets fell to USD 4.5 million from USD 43.9 million at December 31, 2025, and total liabilities fell to USD 5.7 million from USD 50.6 million, leaving a stockholders' Deficit of USD 1.2 million versus USD 8.0 million. General and administrative expense was USD 1.3 million in the quarter, and a USD 1.248 million receivable remained from the asset sale. Preferred Shares convert one-for-one into common stock subject to approval, so the calculated issuance of about 833,333 shares from USD 5.0 million at USD 6.00 would dilute holders. The release lists Nasdaq listing compliance as a risk factor.

Where Things Stand

DNA X, Inc. (NASDAQ:SONM) is indicated up 14.13% in pre-market trading on November 17, 2026, at USD 2.40, a calculated USD 0.30 above a prior close of USD 2.10. No same-day catalyst was identified in published coverage. The most recent reported quarter, ended June 30, 2026, showed zero continuing revenue, a net loss of USD 1.25 million, cash of about USD 0.9 million and 1,488,268 common shares outstanding. Subsequent preferred sales raised USD 5.0 million at USD 6.00 per share. Pre-market moves in a thin, post-reverse-split small-cap can reverse at the 9:30 a.m. ET open, and this is not Investment advice.